(S)-methyl 3-dibenzylamino-butanoate | 1031429-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-methyl 3-dibenzylamino-butanoate
• 英文别名: Methyl (3S)-3-(dibenzylamino)butanoate
• CAS: 1031429-74-9
• 化学式: C₁₉H₂₃NO₂
• 分子量: 297.397
• InChiKey: WLFQLYRDPDIREX-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-methyl 3-dibenzylamino-butanoate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以4.56 g的产率得到(3S)-3-(dibenzylamino)butan-1-ol
  参考文献：
  名称：

  FUSED CYCLIC COMPOUNDS AND USE THEREOF

  摘要：

  The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.

  公开号：

  WO2024120433A1
• 作为产物：
  描述：

  溴甲苯 、 S-3-氨基丁酸甲酯盐酸盐 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以7.49 g的产率得到(S)-methyl 3-dibenzylamino-butanoate
  参考文献：
  名称：

  FUSED CYCLIC COMPOUNDS AND USE THEREOF

  摘要：

  The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.

  公开号：

  WO2024120433A1

文献信息

• Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20030181726A1

  公开（公告）日：2003-09-25

  This invention relates to new aminoalcohol derivatives or salts thereof represented by the following formula [I]: 1 wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  该发明涉及由以下式表示的新氨基醇衍生物或其盐：1其中每个符号如规范中定义或其盐，具有肠道选择性交感兴奋剂、抗溃疡、抗胰腺炎、脂解作用、抗尿失禁和抗排尿活性，以及其制备方法、包含相同的药物组合物，以及用于预防和/或治疗规范中指示的疾病的方法，适用于人类或动物。
• Nitrile Biotransformations for the Synthesis of Highly Enantioenriched β-Hydroxy and β-Amino Acid and Amide Derivatives: A General and Simple but Powerful and Efficient Benzyl Protection Strategy To Increase Enantioselectivity of the Amidase
  作者：Da-You Ma、De-Xian Wang、Jie Pan、Zhi-Tang Huang、Mei-Xiang Wang

  DOI：10.1021/jo800074k

  日期：2008.6.1

  Biotransformations of a number of racemic beta-hydroxy and beta-amino nitrile derivatives were studied using Rhodococcus erythropolis AJ270, the nitrile hydratase and amidase-containing microbial whole cell catalyst, under very mild conditions. The overall enantioselectivity of nitrile biotransformations was governed predominantly by the amidase whose enantioselectivity was switched on remarkably by an O- and a N-benzyl protection group of the Substrates. While biotransformations of beta-hydroxy and beta-amino alkanenitriles gave low yields of amide and acid products of very low enantiomeric purity, introduction of a simple benzyl protection group on the beta-hydroxy and beta-amino of nitrile substrates led to the formation of highly enantioenriched beta-benzyloxy and beta-benzylamino amides and acids in almost quantitative yield. The easy protection and deprotection operations, high chemical yield, and excellent enantioselectivity render the nitrile biotransformation a useful protocol in the synthesis of enantiopure beta-hydroxy and beta-amino acids.
• FUSED CYCLIC COMPOUNDS AND USE THEREOF
  申请人：[en]JACOBIO PHARMACEUTICALS CO., LTD.

  公开号：WO2024120433A1

  公开（公告）日：2024-06-13

  The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.